Tempest Therapeutics’ (TPST) “Outperform” Rating Reaffirmed at William Blair

William Blair reaffirmed their outperform rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a research note published on Wednesday,RTT News reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a research note on Wednesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $20.00.

Tempest Therapeutics Stock Down 8.3 %

Shares of Tempest Therapeutics stock opened at $0.89 on Wednesday. The firm has a market cap of $22.43 million, a price-to-earnings ratio of -0.58 and a beta of -1.78. Tempest Therapeutics has a 52-week low of $0.83 and a 52-week high of $6.00. The company’s 50-day simple moving average is $1.20 and its 200-day simple moving average is $1.95.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Virtu Financial LLC boosted its stake in shares of Tempest Therapeutics by 69.2% during the first quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock valued at $112,000 after acquiring an additional 11,689 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Tempest Therapeutics in the second quarter valued at approximately $55,000. Fullcircle Wealth LLC acquired a new stake in shares of Tempest Therapeutics during the 3rd quarter worth $87,000. Empower Advisory Group LLC acquired a new stake in Tempest Therapeutics during the third quarter worth about $49,000. Finally, XTX Topco Ltd purchased a new position in Tempest Therapeutics in the third quarter valued at approximately $34,000. 22.52% of the stock is owned by hedge funds and other institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.